Clinical Trials
68 trialsA First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
ALX Oncology Inc.
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Seagen Inc.
RAD301
Radiopharm Theranostics, Ltd
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
Rondo Therapeutics
Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers
National Cancer Institute (NCI)
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Seagen Inc.
Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors
Novartis
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Kivu Bioscience Inc.
DELTA-101
Exelixis
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
EvolveImmune United, Inc
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Plexium, Inc.
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Pfizer
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Coherus Oncology, Inc.
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
IDEAYA Biosciences
Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinomas
West China Hospital
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
IDEAYA Biosciences
A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors
Novartis
A Study of MGC026 in Participants With Advanced Solid Tumors
MacroGenics
A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
Prelude Therapeutics
ESCALATE
UMC Utrecht
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
AbbVie
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
Innate Pharma
Endosurgery-02
Shanghai Zhongshan Hospital
A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors
Jacobio Pharmaceuticals Co., Ltd.
A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors
Seagen Inc.
A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.
NeoTX Therapeutics Ltd.
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
Incyte Corporation
A Study of IPM514 in Patients With Esophageal Squamous Cell Carcinoma.
Beijing Immupeutics Medicine Technology Limited
Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies
Novartis
Endostatin Adenovirus With Checkpoint Inhibitor in Advanced Head and Neck or Esophageal Cancer
Sichuan University
A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors
Hoffmann-La Roche
Fraction Dose Escalation of Split-course Hypofractionated Concurrent Chemoradiotherapy Following Induction Chemo-immunotherapy in Unresectable Locally Advanced Esophageal Squamous Carcinoma: a Phase I Study.
Sun Yat-sen University
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
Incyte Corporation
A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands
Novartis
A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma
National Cancer Center, Japan
A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China
Allist Pharmaceuticals, Inc.
Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
Exelixis
Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types
Molecular Templates, Inc.
A Study of KF-0210 in Advanced Solid Tumors Patients
Keythera (Suzhou) Pharmaceuticals Co. Ltd
Liposomal Irinotecan With Cisplatin and Concurrent Radiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma
Hebei Medical University Fourth Hospital
Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies
Symphogen A/S
Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101
Eisai Inc.
Neoadjuvant Adebrelimab With Dalpiciclib for Resectable Esophageal Squamous Cell Carcinomas
West China Hospital
A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies
Atreca, Inc.
HAIC Combined Sintilimab for Liver Metastasis From Esophageal Squamous Cell Carcinoma
Peking University Cancer Hospital & Institute
PALACE-1
Ruijin Hospital
Adjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell Carcinoma
Affiliated Cancer Hospital of Shantou University Medical College
XH-30002 Capsule Combined With Afatinib Tablets for the Treatment of Squamous Cell Carcinoma
Fujian Cancer Hospital
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
Gossamer Bio Inc.